Israel’s Raphael announced positive proof-of-concept clinical study results of its HPC1 non-psychoactive cannabinoid-based formula developed for the treatment of rheumatoid arthritis. 12 adult participants reported lower pain levels and better sleep quality.
https://finance.yahoo.com/news/raphael-pharmaceutical-announces-positive-proof-130000207.html